Scinovex
articleTop 10% cited

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

Clinical Pharmacology & Therapeutics · 1985 · Vol. 38(4) · pp. 402–408
Kōichi NakamuraFumio GotoWayne A. RayC B McAllisterE JacqzG. WilkinsonRobert A. Branch

Abstract

Interethnic differences in debrisoquin and mephenytoin hydroxylation have been compared between normal white (n = 183) and Japanese (n = 100) subjects with the 8-hour urinary metabolic ratio of debrisoquin and the urinary S/R enantiomeric ratio of mephenytoin to identify extensive (EM) and poor (PM) metabolizers. In white subjects the frequency of PMs was 8.7% and 2.7% for debrisoquin and mephenytoin, respectively. In contrast, in Japanese subjects no PMs of debrisoquin were identified, while the incidence of PMs of mephenytoin was 18%. These substantial differences (P less than 0.001) in polymorphic distributions of oxidative drug metabolizing ability have implications for interethnic efficacy and toxicity of drugs and other xenobiotics that are metabolized by the involved cytochrome P-450 isozymes.

Plant-based Medicinal ResearchPharmacogenetics and Drug MetabolismCancer therapeutics and mechanismsMephenytoinDebrisoquineHydroxylationPharmacologyPharmacogeneticsCYP2D6Cytochrome P450Internal medicineChemistryBiology

MeSH terms

Administration, OralAdolescentAdultDebrisoquinFemaleGenotypeHumansHydantoinsHydroxylationIsoquinolinesJapanMaleMephenytoinMiddle AgedPhenotype
Citations
457
FWCI
9.04
field-weighted impact
References
0
Percentile
98%
vs. same field & year
Citations per year
Cited by
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
British Journal of Clinical Pharmacology · 2002 · 578 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.